首页 | 本学科首页   官方微博 | 高级检索  
     


Chemotherapy and resection for gastric cancer with synchronous liver metastases
Authors:Lei Chen  Ming-Quan Song  Hui-Zhong Lin  Lin-Hua Hao  Xiang-Jun Jiang  Zi-Yu Li  Yu-Xin Chen
Affiliation:Department of Surgery,Qingdao Municipal Hospital;Shandong University School of Medicine;Department of Gastroenterology,Qingdao Municipal Hospital;First Institute of Oceanography,State Oceanic Administration;Department of Surgery,Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education),Peking University School of Oncology,Beijing Cancer Hospital and Institute;Department of Surgery, Qilu Hospital Affiliated to Shandong University School of Medicine
Abstract:
AIM: To investigate the effect of surgery and chemotherapy for gastric cancer with multiple synchronous liver metastases (GCLM).METHODS: A total of 114 patients were entered in this study, and 20 patients with multiple synchronous liver metastases were eligible. After screening with preoperative chemotherapy, 20 patients underwent curative gastrectomy and hepatectomy for GCLM; 14 underwent major hepatectomy, and the remaining six underwent minor hepatectomy. There were 94 patients without aggressive treatment, and they were in the non-operative group. Two regimens of perioperative chemotherapy were used: S-1 and cisplatin (SP) in 12 patients, and docetaxel, cisplatin and 5-fluorouracil (DCF) in eight patients. These GCLM patients were given preoperative chemotherapy consisting of two courses chemotherapy of SP or DCF regimens. After chemotherapy, gastrectomy and hepatectomy were preformed. Evaluation of patient survival was by follow-up contact using telephone and outpatient records. All patients were assessed every 3 mo during the first year and every 6 mo thereafter.RESULTS: Twenty patients underwent gastrectomy and hepatectomy and completed their perioperative chemotherapy and hepatic arterial infusion before and after surgery. Ninety-four patients had no aggressive treatment of liver metastases because of technical difficulties with resection and severe cardiopulmonary dysfunction. In the surgery group, there was no toxicity greater than grade 3 during the course of chemotherapy. The response rate was 100% according to the response evaluation criteria in solid tumors criteria. For all 114 patients, the overall survival rate was 8.0%, 4.0%, 4.0% and 4.0% at 1, 2, 3 and 4 years, respectively, with a median survival time (MST) of 8.5 mo (range: 0.5-48 mo). For the 20 patients in the surgery group, MST was 22.3 mo (range: 4-48 mo). In the 94 patients without aggressive treatment, MST was 5.5 mo (range: 0.5-21 mo). There was a significant difference between the surgery and unresectable patients (P = 0.000). Three patients in surgery group were still alive at the end of the cut-off date.CONCLUSION: Perioperative weekly DCF and SP achieved a good response, and combined with surgery, they could improve prognosis of GCLM.
Keywords:Gastric cancer   Liver metastases   Surgery   Chemotherapy   Pilot study
本文献已被 维普 等数据库收录!
点击此处可从《World journal of gastroenterology : WJG》浏览原始摘要信息
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号